menu
    • menu

    Aucta Pharmaceuticals's list of EU CTD Dossiers, Marketing Authorizations, In, Out Licensing Opportunities & Finished Dosage Formulations (FDF) aggregated by PharmaCompass

    Aucta Pharmaceuticals-PSE
    News
    Aucta debuts generic Vimpat

    11 Mar 2024

    // DRUG STORE NEWS

    Aucta Pharmaceuticals Launches First Once-Daily Lacosamide Extended-Release Capsule

    26 Feb 2024

    // PR NEWSWIRE

    Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension

    05 Dec 2022

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    Aucta Read More

    Contact Supplier

    Website

    CPhI Worldwide, Milan

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Aucta is a global brand that creates better products from proven molecules.

    Related CompaniesRelated Companies

    About

    Aucta Pharmaceuticals is an emerging drug product development company focusing on new branded 505(b)(2) products and technology platform-based niche generics. Aucta adopts a branded/generic hybrid model, generating both near-term product revenue and mid- to long-term investment return, aiming to become a significant specialty pharma player in the United States and China marketplace. We focus on developing enhanced products for patients with a therapeutic focus on CNS disorders, as well as Ophthalmics, and Inhalation therapies.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aucta PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    71 Suttons Lane, Piscataway, NJ 08854
    Telephone
    Telephone
    +1 7326400030
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.auctapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aucta-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    China:
    Address:
    Room 301, Building #2, No. 3377 Kangxin Road.
    SIMZ Pudong, Shanghai, P.R.
    China Zip Code: 201318
    Phone: +862158585606
    Fax: +862158585607

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    cphi-worldwide-milan-70313.png

    CPhI Worldwide, Milan

    Attending

    envelop Contact Supplier

    CPhI Worldwide, Milan

    Contact Supplier

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/aucta-pharmaceuticals-llc-party-content-46886.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/aucta-pharmaceuticals-llc-party-content-1623650142.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    NEWS #PharmaBuzz

    read-more
    read-more
    Aucta debuts generic Vimpat
    Aucta debuts generic Vimpat

    11 Mar 2024

    // DRUG STORE NEWS

    https://drugstorenews.com/aucta-debuts-generic-vimpat

    DRUG STORE NEWS
    11 Mar 2024
    Share Share
    Aucta Pharmaceuticals Launches First Once-Daily Lacosamide Extended-Release Capsule
    Aucta Pharmaceuticals Launches First Once-Daily Lacosamide Extended-Release Capsule

    26 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-pharmaceuticals-inc-aucta-pharmaceuticals-launches-motpoly-xr-lacosamide-extended-release-capsules-c-v-the-first-and-only-once-daily-formulation-of-lacosamide-302070783.html

    PR NEWSWIRE
    26 Feb 2024
    Share Share
    Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension
    Aucta announced FDA approval of a generic version of Trileptal®(oxcarbazepine) oral suspension

    05 Dec 2022

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-announced-fda-approval-of-a-generic-version-of-trileptaloxcarbazepine-oral-suspension-301694327.html#:~:text=PISCATAWAY%2C%20N.J.%2C%20Dec.,this%20product%20in%20early%202023.

    PR NEWSWIRE
    05 Dec 2022
    Share Share
    Aucta announces FDA approval of a generic version of Perforomist Inhalation
    Aucta announces FDA approval of a generic version of Perforomist Inhalation

    01 Dec 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/aucta-announces-fda-approval-of-a-generic-version-of-perforomist-formoterol-fumarate-inhalation-solution-301691187.html

    PRNEWSWIRE
    01 Dec 2022
    Share Share
    Aucta's Generic Oxcarbazepine Receives Approval in the U.S.
    Aucta's Generic Oxcarbazepine Receives Approval in the U.S.

    30 Nov 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215332

    FDA
    30 Nov 2022
    Share Share
    Aucta's Generic Formoterol Fumarate Receives Approval in the U.S.
    Aucta's Generic Formoterol Fumarate Receives Approval in the U.S.

    25 Nov 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216486

    FDA
    25 Nov 2022
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") Launches MOTPOLY XR™ (lacosamide) Extended-Release Capsules C-V, the First, and Only Once-Daily ...

    Details:

    Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for the treatment of partial-onset seizures in adults and in pediatric patients.


    Lead Product(s): Lacosamide

    Therapeutic Area: Neurology Brand Name: Motpoly

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 26, 2024

    Aucta Company Banner

    01

    Aucta Pharmaceuticals

    U.S.A
    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Lead Product(s) : Lacosamide

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") Launches MOTPOLY XR™ (lacosamide) Extended...

    Details : Motpoly (lacosamide) is an antiepileptic drug that works by blocking sodium channel alpha subunit. It is being evaluated for the treatment of partial-onset seizures in adults and in pediatric patients.

    Brand Name : Motpoly

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    February 26, 2024

    Aucta Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension

    Details:

    Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat partial seizures.


    Lead Product(s): Oxcarbazepine

    Therapeutic Area: Neurology Brand Name: Trileptal-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 05, 2022

    Aucta Company Banner

    02

    Aucta Pharmaceuticals

    U.S.A
    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Lead Product(s) : Oxcarbazepine

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aucta Announced FDA Approval of A Generic Version of Trileptal®(oxcarbazepine) Oral Suspension

    Details : Oxcarbazepine produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. It is indicated to treat parti...

    Brand Name : Trileptal-Generic

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    December 05, 2022

    Aucta Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Aucta Announces FDA Approval Of A Generic Version Of Perforomist® (formoterol fumarate) Inhalation Solution

    Details:

    Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).


    Lead Product(s): Formoterol Fumarate

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Formoterol Fumarate-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable December 01, 2022

    Aucta Company Banner

    03

    Aucta Pharmaceuticals

    U.S.A
    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Lead Product(s) : Formoterol Fumarate

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Aucta Announces FDA Approval Of A Generic Version Of Perforomist® (formoterol fumarate) Inhalatio...

    Details : Formoterol Fumarate is a long-acting bronchodilator used as a long-term treatment to prevent or decrease wheezing and trouble breathing caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchiti...

    Brand Name : Formoterol Fumarate-Generic

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    December 01, 2022

    Aucta Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle (Deferasirox Granules)

    Details:

    JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.


    Lead Product(s): Deferasirox

    Therapeutic Area: Hematology Brand Name: Jadenu

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Oakrum Pharma, LLC

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 22, 2021

    Aucta Company Banner

    04

    Aucta Pharmaceuticals

    U.S.A
    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAucta is a global brand that creates better products from proven molecules.

    Lead Product(s) : Deferasirox

    Therapeutic Area : Hematology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Oakrum Pharma, LLC

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle ...

    Details : JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

    Brand Name : Jadenu

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 22, 2021

    Aucta Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search